Anzeige
Mehr »
Login
Dienstag, 21.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
STRONG BUY! Kurs eskaliert - A Star is Born!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40WFS | ISIN: SE0023287347 | Ticker-Symbol: 5ZD0
Frankfurt
21.01.25
08:05 Uhr
0,457 Euro
+0,013
+2,93 %
Branche
Unterhaltung
Aktienmarkt
Sonstige
1-Jahres-Chart
FRAGBITE GROUP AB Chart 1 Jahr
5-Tage-Chart
FRAGBITE GROUP AB 5-Tage-Chart
RealtimeGeldBriefZeit
0,4730,53413:21
GlobeNewswire (Europe)
124 Leser
Artikel bewerten:
(0)

Fragbite Group AB: Fragbite Group strengthens the balance sheet with loans of 5 MSEK

Finanznachrichten News

Fragbite Group AB (publ) ("Fragbite Group" or 'the Company') has taken up loans in the aggregate of 5 MSEK in order to strengthen its balance sheet. The lenders are a group of existing shareholders in the Company who wish to support and accelerate Fragbite Group's growth. The loans mature on 16 July 2025 and can be converted into shares at the Company's initiative and with the approval of the lenders on two specified occasions.

Fragbite Group has today signed agreements for loans at a total of 5 MSEK which mature on 16 July 2024. The lenders are a group of investors, all of which already own shares in Fragbite Group and wish to support and accelerate the Company's growth. The lenders include some of the Company's largest shareholders.

"After a successfully implemented cost reduction programme, an intensive fall with business development and the recently finalised subscription period of warrants, Fragbite Group now has a good foundation to stand on. With the outcome of the warrants, an important piece of the puzzle fell into place enabling us to plan for the coming year. It is the assessment of myself and the Board that the Company benefits from further strengthening the balance sheet to meet the opportunities we have in front of us in 2025 and ensure good liquidity for the remainder of 2024. With this loan, we also tie a group of committed shareholders closer to the Company, and I wish to take the opportunity to thank them for their support and their faith in the future of Fragbite Group," says Stefan Tengvall, CEO, Fragbite Group.

The loans mature on 16 July 2025, and the Company may repay the loans in full or in part at any time until that date. The loans include a 5 percent arrangement fee and a fixed interest rate of 10 percent payable on or before 16 July 2025 in the event of full repayment or full conversion into shares. The Company has the right to offer each respective lender to convert his/her entire loan, including arrangement fee and interest, into shares on two occasions. If the lender accepts the offer, the following pricing applies:

  • Occasion 1 - 31 December 2024: the conversion price per share is set to the lowest of either SEK 0.03 or the volume weighted average price ("VWAP") for the 20 trading days immediately preceding the conversion date, with a 20 percent discount.
  • Occasion 2 - 15 July 2025: the conversion price per share is set to the VWAP for the 20 trading days immediately preceding the conversion date, with a 20 percent discount.

The Board of Directors is of the opinion that the loan is at market rate and taken for the purpose of financial sustainability. In the case of a lender being prevented from converting his/her loan to shares on the two occasions set out in the agreement due to applicable insider trading legislation, the Company has the right to offer such lender the opportunity to convert to shares as soon as he/she is no longer prevented from doing so.

Each lender undertakes not to borrow Fragbite Group shares and sell such borrowed shares in the market, so-called short selling, prior to the full repayment of the loan on the maturity date or, if applicable, prior to a conversion of said loan into shares.

For questions, please contact:

Erika Mattsson, Chief Communications Officer
em@fragbitegroup.com
Phone: +46 8 520 277 82

Redeye AB is the Company's Certified Adviser.

About us

Fragbite Group (publ) is a Swedish corporate group with a portfolio of established subsidiaries that develop, adapt and publish games and esports content within GAMING, ESPORTS and WEB3. Our products are developed for both traditional platforms - PC, mobile and console - and modern platforms built on blockchain technology. The Group is headquartered in Stockholm and listed on Nasdaq First North Growth Market.

This information is information that Fragbite Group AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-10-30 14:28 CET.

© 2024 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.